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among the variables of dose and SF were studied by the 
Spearman correlation coefficient. Differences in SF related to 
maximum doses to the sphincter were assesed by the Mann-
Whitney test. 
 
Results: Wexner scaleMean Wexner score was 5.5 points 
higher in those patients with V20>0 compared to those for 
which V20=0 (p=0.008). In a multivariate regression model, 
results suggest that the effect of V20 on poor anal sphincter 
control is independent of the effect of distance, with an 
adjusted OR of 3.42 (1.09, 10.72). 
 
Conclusion: In order to improve the SF, the maximum dose of 
radiation to the AS should be limited, when possible, to < 20 
Gy 
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Purpose or Objective: Anal cancer is a relatively rare 
cancer, making up approximately 0.4% of all new diagnoses of 
cancer. In 2011, there were 1,175 new cases of anal cancer 
diagnosed in the UK. The current standard treatment is 
radical chemoradiotherapy. We conducted a retrospective 
case series of anal squamous cell carcinoma treated in the 
regional radiation oncology network between 2008 and 2014 
inclusive to examine recent management practice and 
outcome of anal squamous cell carcinoma.  
 
Material and Methods: Patients were identified from the 
regional radiation oncology cancer database. Data was 
collected retrospectively from ARIA® oncology information 
system and patient charts. Information was collected in 
relation to demographic details, radiotherapy dose and 
regimen, chemotherapy regimen, persistence and recurrence 
of disease, salvage surgery rates, and survival analysis. 
Statistical analyses were carried out using IBM® SPSS® 
statistical software version 21.0. 
 
Results: 79 cases of anal squamous cell carcinoma were 
identified. Mean age at commencement of radiotherapy was 
60.2 years (+/-13.2 years). 29 patients were male (36.7%) and 
50 (63.3%) were female. 8 (10.1%) patients had documented 
HIV infection. 74 (93.7%) patients were treated with radical 
chemoradiotherapy. The most common total radiotherapy 
dose delivered was 50.4 Gy in 28 fractions (N=58; 73.4%) (see 
table 1). The majority of patients (N=67; 84.8%) received 
combination chemotherapy with mitomycin C and 5-FU. 2 
(2.5%) patients who received radical treatment had 
persistent disease following radiotherapy. 5 (6.3%) patients 
had loco-regional recurrence and 3 (3.8%) patients developed 
solid organ metastases following complete treatment 
response at the primary. 4 patients had salvage surgery. 
Survival was measured from the initiation of radiotherapy 
treatment using the Kaplan–Meier method. Overall survival 
was 98%, 90%, 83% and 83% at 1, 2, 3 and 4 years 
respectively. Disease free survival was 91%, 77%, 74% and 74% 
at 1, 2, 3 and 4 years respectively (see fig. 1). 
 
 
 
 
 
Conclusion: Our study found that the majority of patients in 
our radiation oncology network were treated with 
chemoradiotherapy in line with international guidelines. In 
our study, chemoradiotherapy in the treatment of anal 
squamous cell carcinoma was associated with a high 
complete response rate and a low treatment failure rate. 
Treatment and outcomes in our study are consistent with 
international trial data. 
 
EP-1290  
A review of grade 3 bowel toxicity in patients treated with 
chemoradiotherapy for rectal cancer 
J.A. King1, L. Davidson1, N. Alam1, C. Arthur1, C. McBain1, A. 
Mirza1, M. Saunders1, V. Misra
1The Christie NHS Foundation Trust, Clinical Oncology, 
Manchester, United Kingdom 
1 
 
Purpose or Objective: Concurrent chemoradiotherapy (CRT) 
is the standard treatment for locally advanced rectal cancer 
to downstage disease prior to definitive surgery. Previous 
studies report ≥ grade 3 (G3) bowel toxicity of 3 -4%; 
QUANTEC recommend small bowel V45 <195 cm3 to reduce 
G3 toxicity. We noted an increase in G3 bowel toxicity in the 
period Sept – Dec 2014 in our institution and aimed to 
determine the cause.  
 
Material and Methods: We retrospectively identified patients 
who received pre-operative long-course CRT for rectal cancer 
between Sept – Dec 2014 and Jan - April 2014 (control), and 
reviewed case notes and radiotherapy (XRT) plans. Small 
bowel V45 was calculated for each patient. G3 toxicity was 
defined as per the CTCAE grading system for diarrhoea, 
abdominal pain and vomiting.  
 
Results: Fifty patients were identified: Jan – April cohort 
(n=28) was compared to Sept – Dec cohort (n=22). Both 
groups were similar for patient demographics, CRT treatment 
volumes and doses, patient positioning and XRT delivery 
technique. Two of 28 patients (9%) in Jan – April cohort had 
G3 bowel toxicity; both were admitted for symptom control. 
Six of 22 patients (27%) in Sept – Dec cohort developed G3 
bowel toxicity; 5 (23%) required admission.  
G3 toxicity occurred after a minimum of 16 fractions (range 
16-21). All patients had normal bowel function prior to 
